Down 4% in 3 days, should you buy the dip on CSL shares?

Could the biotech company's shares go higher? Let's take a look.

| More on:
A young woman sits with her hand to her chin staring off to the side thinking about her investments.

Image source: Getty Images

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

Key points

  • The CSL share price has slid 4% in the past three trading days
  • However, one broker has recently tipped a near 18% upside for the CSL share price
  • CSL shares have climbed 5% in the last year 

The CSL Limited (ASX: CSL) share price has descended in the past three trading days, but is it a buy?

CSL shares have slid 3.88% since market close on Wednesday to $288.41. For perspective, the benchmark S&P/ASX 200 Index (ASX: XJO) has fallen 1.57% in the same time frame.

Let's take a look at the outlook for CSL shares.

Is CSL a buy?

CSL is a global biotechnology company consisting of multiple business arms including CSL Behring, CSL Vifor, and Seqirus. The company has more than 300 plasma collection centres around the world.

Bell Potter analysts are optimistic about CSL amid the company's latest CSL Vifor acquisition. Bell Potter also sees the global growth in plasma volumes as a potential positive for the CSL share price. The team said:

The recently completed acquisition of Vifor Pharma will add global leadership in pharmaceutical products for renal disease and iron deficiency.

The global growth in plasma volumes is expected to be around a solid 8% per annum for the foreseeable future and, in addition, the group is planning to launch new products from its very extensive Research and Development portfolio.

Citi also has a "buy" rating on the CSL share price with a $340 price target. This implies a nearly 18% upside based on the current price.

As my Foolish colleague James reported on Friday, strong demand for CSL's immunoglobulins and the company's "lucrative" research and development pipeline could see the company in a strong position for growth in the long term.

CSL announced the news of a CEO succession plan last week. The company's CEO Paul Perreault is set to step down in March, with chief operating officer Dr Paul McKenzie taking over the top job. Commenting on the appointment, CSL chair Brian McNamee said:

Paul McKenzie is a patient-focused global leader with a demonstrated track record of leading complex organisations and delivering outstanding business results.

Earlier this month, CSL officially opened a brand new $900 million blood plasma processing site in Melbourne.

CSL share price snapshot

The CSL share price has climbed 5% in the past year. In the past month, it has slipped 2%.

CSL has a market capitalisation of about $139 billion.

Motley Fool contributor Monica O'Shea has no position in any of the stocks mentioned. The Motley Fool Australia's parent company Motley Fool Holdings Inc. has positions in and has recommended CSL. The Motley Fool Australia has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips.

More on Healthcare Shares

Cropped shot of an attractive young female scientist working on her computer in the laboratory.
Healthcare Shares

CSL share price leaping higher amid $1.9 billion funding news

ASX 200 investors are bidding up the CSL share price on Wednesday.

Read more »

Two happy scientists analysing test results.
Healthcare Shares

Mesoblast share price rockets 36% on breaking FDA news

ASX investors are sending the Mesoblast share price soaring following promising FDA news.

Read more »

a doctor in white coat and stethoscope stands in front of a building holding an electronic device in his hands.
Healthcare Shares

Guess which ASX 200 healthcare share is jumping 7% on a guidance update

This healthcare share is performing better than expected in FY 2024.

Read more »

a biomedical researcher sits at his desk with his hand on his chin, thinking and giving a small smile with a microscope next to him and an array of test tubes and beackers behind him on shelves in a well-lit bright office.
Earnings Results

Chemist Warehouse merger target Sigma reports 149% FY24 profit jump

This could be the last set of results from Sigma as we know it if its merger is approved.

Read more »

Cropped shot of an attractive young female scientist working on her computer in the laboratory.
Healthcare Shares

1 ASX healthcare stock that looks severely undervalued

I think this stock looks too cheap to miss.

Read more »

Stethoscope with a piggy bank and hundred dollar notes.
Healthcare Shares

Own Medibank shares? Here's why it's a rewarding day for you

Shareholders are getting a healthy boost today.

Read more »

Health professional looking at a laptop.
Healthcare Shares

Are CSL shares a must-buy in March?

Let's see what analysts are saying about this high-quality company.

Read more »

A woman jumps for joy with a rocket drawn on the wall behind her.
Healthcare Shares

This ASX healthcare stock is up 72% on FDA news and 'historic moment'

Huge gains are been recorded by this stock on Tuesday. But why?

Read more »